日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Quantifying CD73 expression after chemotherapy or chemoradiotherapy in esophageal squamous cell carcinoma.

定量分析食管鳞状细胞癌化疗或放化疗后 CD73 的表达

期刊:Discover Oncology
影响因子:2.9
doi:10.1007/s12672-025-02179-x
Cooper Zachary A, Wang Ying, Martin Philip L, Murayama Kosho, Kumar Rakesh, Kato Ken, Yamamoto Shun, Sekine Shigeki
细胞生物学
肿瘤免疫
发表日期：2025
文献求助 收藏

Ceralasertib, an ATR kinase inhibitor, as monotherapy in Japanese patients with advanced solid malignancies: Results from a phase 1 study

Ceralasertib（一种 ATR 激酶抑制剂）单药治疗日本晚期实体恶性肿瘤患者：一项 1 期研究的结果

期刊:Investigational New Drugs
影响因子:2.7
doi:10.1007/s10637-025-01592-x
Kuboki, Yasutoshi; Matsubara, Nobuaki; Nakajima, Hiromichi; Fujisawa, Takao; Koyama, Takafumi; Sato, Jun; Katsuya, Yuki; Kmieciak, Aleksandra; Slade, Daniel; Iwata, Kiyomi; Takahashi, Yusuke; Nii, Masahiro; Murayama, Kosho; Kawata, Toshio; Kawasumi, Hisashi; Yamamoto, Noboru
信号转导
肿瘤
肿瘤免疫
ATR
发表日期：2025
文献求助 收藏

Safety and pharmacokinetics of imaradenant (AZD4635) in Japanese patients with advanced solid malignancies: a phase I, open-label study

伊玛拉丹南（AZD4635）在日本晚期实体恶性肿瘤患者中的安全性和药代动力学：一项I期开放标签研究

期刊:Cancer Chemotherapy and Pharmacology
影响因子:2.3
doi:10.1007/s00280-023-04605-9
Matsubara, Nobuaki; Kusuhara, Shota; Yamamoto, Noboru; Sudo, Kazuki; Yanagita, Masahiko; Murayama, Kosho; Kawasumi, Hisashi; Russell, Deanna L; Yin, Da; Shimizu, Toshio
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

Safety, tolerability, pharmacokinetics, and antitumour activity of oleclumab in Japanese patients with advanced solid malignancies: a phase I, open-label study

oleclumab 在日本晚期实体恶性肿瘤患者中的安全性、耐受性、药代动力学和抗肿瘤活性：一项 I 期开放标签研究

期刊:International Journal of Clinical Oncology
影响因子:2.8
doi:10.1007/s10147-022-02242-5
Kondo, Shunsuke; Iwasa, Satoru; Koyama, Takafumi; Fujita, Tomoko; Sugibayashi, Ko; Murayama, Kosho; Yamamoto, Noboru
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: a phase 1 study

一项针对日本晚期实体恶性肿瘤患者的I期研究，旨在评估靶向STAT3的反义寡核苷酸（danvatirsen）单药治疗及联合度伐利尤单抗治疗的安全性、耐受性、药代动力学和初步抗肿瘤活性。

期刊:BMJ Open
影响因子:2.3
doi:10.1136/bmjopen-2021-055718
Nishina, Tomohiro; Fujita, Tomoko; Yoshizuka, Naoto; Sugibayashi, Ko; Murayama, Kosho; Kuboki, Yasutoshi
JAK/STAT
STAT3
肿瘤
肿瘤免疫
发表日期：2022
文献求助 收藏

Safety and antitumor activity of acalabrutinib for relapsed/refractory B-cell malignancies: A Japanese phase I study

acalabrutinib治疗复发/难治性B细胞恶性肿瘤的安全性和抗肿瘤活性：一项日本I期研究

期刊:Cancer Science
影响因子:4.3
doi:10.1111/cas.14886
Izutsu, Koji; Ando, Kiyoshi; Ennishi, Daisuke; Shibayama, Hirohiko; Suzumiya, Junji; Yamamoto, Kazuhito; Ichikawa, Satoshi; Kato, Koji; Kumagai, Kyoya; Patel, Priti; Iizumi, Sakura; Hayashi, Nobuya; Kawasumi, Hisashi; Murayama, Kosho; Nagai, Hirokazu
B细胞
肿瘤
肿瘤免疫
细胞生物学
免疫/内分泌
发表日期：2021
文献求助 收藏